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Meta-Analysis of Associations of the Ser217Leu and
Ala541Thr Variants in ELAC2 (HPC2) and Prostate
Cancer
To the Editor:
Several factors can contribute to variability in association-
study findings. They include, but are not limited to, pop-
ulation-specific linkage disequilibrium between causal
variants and marker variants, multilocus interactions,
gene-environmental interactions, inadequate statistical
power, and different selection criteria for case and con-
trol individuals. Meta-analyses afford the opportunity
to combine evidence across studies, thereby increasing
sample size and power and allowing a more global in-
terpretation of the total data available. We have per-
formed a meta-analysis for data pertaining to the as-
sociation of alleles of variants Ser217Leu (MIM
605367.0001) and Ala541Thr (MIM 605367.0002) in
the ELAC2 (HPC2) gene (MIM 605367) and prostate
cancer (MIM 176807) (GenBank accession number
AF304370).
The ELAC2 gene on chromosome 17p11.2 was the
first candidate gene for prostate cancer susceptibility to
be identified from a linkage analysis and positional clon-
ing project (Tavtigian et al. 2001). Two segregating
mutations (1641insG and Arg781His) were found in
two extended Utah pedigrees; in addition, the less
common alleles of two missense variants (Ser217Leu
and Ala541Thr) were observed to be associated with
familial prostate cancer (from pedigrees at high risk of
prostate cancer [ ]) when compared with controlnp 429
individuals at low risk (i.e., men who were cancer-free
and were not members of pedigrees with a high risk of
prostate cancer [ ]). Initial results indicated thatnp 148
individuals homozygous for Leu217 and individuals car-
rying the Thr541 allele were at significantly increased
risk for prostate cancer and, furthermore, that a com-
bination across both genotypes was the most significant,
with an odds ratio (OR) of 2.94 (95% CI 1.52–5.69)
(see table 3 of Tavtigian et al. 2001).
Several groups have attempted to confirm these find-
ings, with varying levels of success (only two of the total
six studies found significant evidence for the same var-
iants). In brief, Rebbeck et al. (2000) found that carriage
of both Leu217 and Thr541 significantly was associated
with prostate cancer, in a study of 359 men with newly
diagnosed prostate cancer and 266 male age- and race-
matched control individuals with an OR of 2.37 (95%
CI 1.06–5.29) (see table 2 of Rebbeck et al. 2000). Xu
et al. (2001) studied two groups of patients: those with
familial disease ( 4) and those with sporadic dis-np 13
ease ( 8), in comparison with control individualsnp 22
at low risk (men who had normal results of a digital
rectal examination [DRE] and normal levels of prostate-
specific antigen [PSA] [ ]). No analyses yieldednp 182
significant results, although several exhibited trends in
the expected direction; for example, the OR for carriers
of Leu217 compared with control individuals was 1.49
(95% CI 0.94–2.35) (see table 5 of Xu et al. [2001]).
Vesprini et al. (2001) studied 431 men with screen-
detected prostate cancer, 513 men with elevated PSA but
no detectable prostate cancer (the prevalence of benign
and neoplastic prostate disease in this group was high),
and 922 healthy women. No significant results were
found, with the most interesting finding from this study
being that there were more double homozygotes among
the men with prostate cancer than among either control
group ( ) and, in addition, that there was a mod-Pp .18
est association between carriage of Thr541 and a family
history of prostate cancer ( ). Suarez et al. (2001)Pp .04
studied 257 men with familial prostate cancer and 355
low-risk control individuals (i.e., those with normal
DRE results and normal PSA levels, age 165 years, and
no family history of prostate cancer); they found a non-
significant trend for carriage of Leu217 and a significant
association between carriage of the Thr541 allele and
prostate cancer ( ). Wang et al. (2001) foundPp .008
no evidence for an association of either variant when
446 men with familial prostate cancer were compared
with 502 population-based control individuals; however,
a novel germline nonsense mutation (Glu216Stop) was
found to play an interesting role in a large nuclear family
that included multiple individuals with prostate cancer.
Rokman et al. (2001) studied 107 men with familial
prostate cancer, 467 men with sporadic disease, 223men
with benign prostatic hyperplasia (BPH), and 568 male
blood donors. The Leu217 and Thr541 alleles were not
found to be elevated significantly in men with prostate
cancer (familial or sporadic); however, Thr541was found
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Table 1
Raw Genotypic Counts for Ser217Leu and Ala541Thr
VARIANT
AND GENOTYPE
AUTHOR (RACE OF STUDY POPULATION)
Rebbeck
(Various)a
Suarez
(White)b
Tavtigian
(White)c
Vesprini
(Various)d Wang (White) Xu (White)f Xu (White)g
Case Control Case Control Case Control Case Control Case Control Case Control Case Control
Ser217Leu:
SS 144 118 120 190 204 76 220 259 198 232 58 97 172 97
SL 139 111 114 134 168 63 169 213 205 221 61 71 156 71
LL 17 21 23 31 57 9 42 41 41 49 15 14 34 14
Total 300 250 257 355 429 148 431 513 444 502 134 182 362 182
Ala541Thr:
AA 269 232 232 342 387 143 404 478 399 450 111 166 322 166
AT,TT 21 8 25 13 42 5 27 35 46 52 13 16 34 16
Total 290 240 257 355 429 148 431 513 445 502 124 182 356 182
a Table 2 of Rebbeck et al. (2000) with additional clarification from the authors to enable Ser217 recessive analysis; 180% of patients were
white, and case and control individuals were race and age matched.
b Table 1 of Suarez et al. (2001).
c From table 3 of Tavtigian et al. (2001), with counts for SS and SL separated.
d From table 2 of Vesprini et al. (2001). Only male control individuals were included in the present analysis; 180% of the study population
were white.
e From tables 4 and 5 of Wang et al. (2001). Case individuals were ascertained from 181 families (180 white non-Hispanic and 1 of Hispanic
ancestry).
f Patients with familial prostate cancer only; from table 5 of Xu et al. (2001).
g Patients with either familial or sporadic cancer; from table 5 of Xu et al. (2001).
to be significantly elevated in men with BPH, and the
rare allele of a novel variant (Glu622Val) was found to
be significantly increased in both groups with prostate
cancer. All studies found Thr541, the less common var-
iant, to be in very strong disequilibrium with Leu217.
This disequilibrium makes it essentially impossible to
distinguish the effects of Thr541 alone from the joint
effect of the two missense changes in the Leu217 
Thr541 allele.
We constructed a Mantel-Haenszel meta-analysis of
data from these studies, to consolidate the evidence of
association between alleles of Ser217Leu andAla541Thr
and prostate cancer. The Mantel-Haenszel x2 test and
the Mantel-Haenszel estimate of the OR (e.g., see Kirk-
wood 1988) were used to provide a summary test and
OR, which control for confounding factor(s)—across the
various data sources—that may distort results if data are
simply pooled. Data from Rokman et al. (2001) could
not be incorporated, since their data were presented by
allele rather than by genotype. As is evident from the
brief descriptions given here, classifications for affected
and control individuals varied substantially across stud-
ies. For this reason, we analyzed case and control in-
dividuals in three groupings: men with familial prostate
cancer versus low-risk control individuals (FAM vs.
LOW); all men with prostate cancer versus low-risk con-
trol individuals (ALL vs. LOW); and all men with pros-
tate cancer versus all control individuals (ALL vs. ALL).
Table 1 shows the raw genotypic counts from the studies
used in our analyses, and table 2 reports the results for
each of the three case/control comparison groups for
Leu217 (recessive and dominant), Thr541 (dominant),
and a multilocus analysis across both variants (Leu217
dominant and Thr541 dominant).
Our summary analysis of Thr541 data argues strongly
in favor of two points. First, there is substantial evidence
that carriage of the Thr541 allele, either alone or in
combination with carriage of the Leu217 allele, is sig-
nificantly associated with prostate cancer. Results of the
comparisons FAM versus LOW and ALL versus LOW
are highly significant for both these tests (Pp .0080–
). Second, the results are most significant in the.00011
more extreme case/control comparison group (FAM vs.
LOW), with effect sizes decreasing as the case/control
comparison broadens. For example, for the Thr541
dominant analysis, the ORs decrease from 1.96 (95%
CI 1.19–3.22) to 1.81 (95%CI 1.23–2.68) to 1.25 (95%
CI 0.97–1.60) (without data of Tavtigian et al. [2001]),
or, similarly, from 2.23 (95% CI 1.44–3.46) to 2.01
(95% CI 1.40–2.88) to 1.35 (95% CI 1.07– 1.72) (with
data of Tavtigian et al. [2001]) as the comparison groups
are expanded from FAM versus LOW to ALL versus
LOW to ALL versus ALL, respectively. The dilution of
significance and risk-size estimate as the case/control
comparison group broadens is to be expected and is
consistent with a true genetic risk. Patients with sporadic
cancer are more likely to have a larger environmental
and smaller genetic component, and population control
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Table 2
Results of Mantel-Haenszel Meta-Analysis, Including and Excluding Data of Tavtigian et al. (2001) for the Three Case/Control
Comparisons
COMPARISON, INCLUSIVENESS,
AND MEASUREa
ANALYSIS
Leu217 Dominant Leu217 Recessive Thr541 Dominant Multilocusb
FAM vs. LOW:
Without Tavtigian:
P .017 .48 .0080 .0026
OR (95% CI) 1.37 (1.06–1.78) 1.18 (.75–1.85) 1.96 (1.19–3.22) 2.21 (1.32–3.69)
Total sample size 928 928 918 529
With Tavtigian:
P .016 .044 .00033 .00011
OR (95% CI) 1.30 (1.05–1.61) 1.48 (1.01–2.16) 2.23 (1.44–3.46) 2.44 (1.55–3.83)
Total sample size 1,505 1,505 1,495 856
ALL vs. LOW:
Without Tavtigian:
P .11 .81 .0029 .0023
OR (95% CI) 1.17 (.96–1.42) .96 (.67–1.37) 1.81 (1.23–2.68) 1.86 (1.25–2.77)
Total sample size 1,706 1,706 1,680 985
With Tavtigian:
P .075 .31 .00014 .00012
OR (95% CI) 1.17 (.98–1.39) 1.18 (.86–1.62) 2.01 (1.40–2.88) 2.05 (1.42–2.96)
Total sample size 2,283 2,283 2,257 1,312
ALL vs. ALL:
Without Tavtigian:
P .21 .86 .081 NA
OR (95% CI) 1.09 (.95–1.24) 1.02 (.81–1.29) 1.25 (.97–1.60) NA
Total sample size 3,596 3,596 3,571 NA
With Tavtigian:
P .15 .29 .013 NA
OR (95% CI) 1.10 (.97–1.24) 1.13 (.90–1.41) 1.35 (1.07–1.72) NA
Total sample size 4,173 4,173 4,148 NA
a FAM vs. LOW comparison includes data from Xu et al. (2001) (familial prostate cancer only) and Suarez et al. (2001). ALL
vs. LOW comparison includes data from Xu et al. (2001) (familial and sporadic prostate cancer), Suarez et al. (2001), and Rebbeck
et al. (2000). ALL vs. ALL comparison includes data from Xu et al. (2001) (familial and sporadic prostate cancer), Suarez et al.
(2001), Rebbeck et al. (2000), Vesprini et al. (2001) (male control individuals only), and Wang et al. (2001).
b Association test for carriage of both Leu217 and Thr541 versus carriage of neither. “NA” indicates that data were not available
from the relevant published papers to perform the multilocus analysis.
individuals are likely to harbor a substantial portion of
men with prostate cancer, given the high disease rate.
The summary analysis of Leu217 data does not sup-
port the original finding by Tavtigian et al. (2001) that
homozygotes for Leu217 are at increased risk for pros-
tate cancer. Evidence from the meta-analysis is consistent
with a very modest dominant effect. This may indicate
that the best model for Leu217 is codominant. Signifi-
cant results for Leu217 dominant are weaker than those
for Thr541, but, as with Thr541, there appears to be a
dilution of the effect of Leu217 as the case/control com-
parison broadens. Leu217 results are more often signif-
icant in the most extreme (FAM vs. LOW) case/control
comparison and are never significant in the broadest
(ALL vs. ALL) comparison. Also supportive of a very
modest effect of Leu217 are the ORs for the combined
multilocus analysis, which were found to be consistently,
although modestly, higher than ORs for the Thr541
dominant analysis.
Our analyses here suggest that the original maximal
OR risk estimates of 3.1 (carriage of Thr541 under a
FAM vs. LOW comparison [table 3 of Tavtigian et al.
2001) and 2.37 (carriage of Thr541 under an ALL vs.
LOW comparison [table 2 of Rebbeck et al. 2000]) for
ELAC2 variants on prostate cancer risk were inflated.
Summary results indicate risk ratios as high as 2.4 when
highly discordant groups (FAM vs. LOW, in the multil-
ocus analysis including Tavtigian data) are compared,
but the results project much lower risks, in the range of
1.3 (ALL vs. ALL, in the Thr541 dominant analyses),
for the risk in the general population. If we assume a
carrier frequency of 6.6% for risk genotypes (using
pooled data), an OR of 1.3 translates to a population-
attributable risk of 2% (Lillienfeld and Lillienfeld 1980).
This is perhaps a more realistic expectation for common
variants in a complex disease, and it suggests that studies
may have been underpowered. In conclusion, our sum-
mary analyses indicate convincing evidence for the role
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of ELAC2 in prostate cancer, suggest moderate familial
risk, and estimate that risk genotypes in ELAC2 may
cause 2% of prostate cancer in the general population.
NICOLA J. CAMP1 AND SEAN V. TAVTIGIAN2
1Genetic Epidemiology, Department of Medical
Informatics, University of Utah Medical School,
and 2Genetic Cancer Susceptibility Unit, International
Agency for Research of Cancer, Lyon, France
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for prostate cancer [MIM
176807], HPC2/ELAC2 [MIM 605367], Ser-to-Leu change
at amino acid 217 [MIM 605367.0001], and Ala-to-Thr
change at amino acid 541 [MIM 605367.0002]
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for variant
Ser217Leu [AF304370])
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Regarding “Testing for Population Subdivision and
Association in Four Case-Control Studies”
To the Editor:
Ardlie et al. (2002) recently found no evidence for pop-
ulation structure in separate case-control studies of type
2 diabetes and hypertension in U.S. whites and only
weak evidence of structure in a case-control study of
hypertension in African Americans. These results are
consistent with the theoretical results of Wacholder et
al. (2000), who found that the magnitude of bias due
to unrecognized population stratification is likely to be
small under most plausible scenarios. To further evaluate
the potential bias due to stratification for these and other
conditions, we conducted a series of case-control studies
for six common phenotypes in a population-based sam-
ple of U.S. adults.
The study population included 444 unrelated adults
(231 African Americans and 213 non-Hispanic whites)
randomly selected from five U.S. communities as part of
theHypertensionGenetic EpidemiologyNetwork (Hyper-
GEN) of the National Heart, Lung, and Blood Institute
(NHLBI) Family Blood Pressure Program (Williams et al.
2000). The studywas approved by the institutional review
boards at each institution, and appropriate informed con-
sent was obtained from human subjects. Phenotypesmea-
sured included: (1) obesity ( ), (2) hypercholes-BMI  30
terolemia (total plasma mg/dl orcholesterol 240
current use of medications to lower cholesterol), (3) hy-
pertension (systolic blood mmHg, dia-pressure  140
stolic blood mmHg, or current use of med-pressure  90
ications to lower blood pressure), (4) diabetes (fasting
serum mg/dl, nonfastingglucose  126 glucose  200
mg/dl, self-reported physician diagnosis of diabetes, or
current use of hypoglycemic medications), (5) renal dys-
function (serum creatinine  sex-specific 90th percentile
[1.4 mg/dl in men and 1.1 mg/dl in women]), and (6)
cardiovascular disease (self-reported history of heart at-
tack, stroke, or coronary artery bypass surgery). For each
